Everninomicin | CAS# 53024-98-9 | oligosaccharide antibiotic

MedKoo Cat#: 414166 | Name: Everninomicin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Everninomicin is a new oligosaccharide antibiotic

Chemical Structure

Everninomicin

CAS#53024-98-9

Theoretical Analysis

MedKoo Cat#: 414166

Name: Everninomicin

CAS#: 53024-98-9

Chemical Formula: C70H97Cl2NO38

Exact Mass: 1629.5066

Molecular Weight: 1631.42

Elemental Analysis: C, 51.54; H, 5.99; Cl, 4.35; N, 0.86; O, 37.27

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Everninomicin

IUPAC/Chemical Name

(2R,3R,4R,6S)-6-(((3a'R,4R,4'R,5S,6R,6'S,7'S,7a'R)-6'-(((2S,3R,4S,5S,6R)-2-(((2R,4S,6S)-6-(((2R,3aS,3a'R,6S,7R,7aS,7'R,7a'S)-7'-((2,4-dihydroxy-6-methylbenzoyl)oxy)-7-hydroxyoctahydro-4H-2,4'-spirobi[[1,3]dioxolo[4,5-c]pyran]-6-yl)oxy)-4-hydroxy-5-methoxy-2-(methoxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-3-hydroxy-5-methoxy-6-methyltetrahydro-2H-pyran-4-yl)oxy)-4,7'-dihydroxy-4',6,7a'-trimethyloctahydro-4'H-spiro[pyran-2,2'-[1,3]dioxolo[4,5-c]pyran]-5-yl)oxy)-4-(((2R,4S,5R,6S)-5-methoxy-4,6-dimethyl-4-nitrotetrahydro-2H-pyran-2-yl)oxy)-2-methyltetrahydro-2H-pyran-3-yl 3,5-dichloro-4-hydroxy-2-methoxy-6-methylbenzoate

InChi Key

UPADRKHAIMTUCC-JBNGTWNESA-N

InChi Code

InChI=1S/C70H97Cl2NO38/c1-24-15-31(74)16-32(75)40(24)61(82)100-36-22-94-70(60-53(36)92-23-93-60)108-37-21-91-63(46(79)52(37)109-70)106-65-56(89-13)45(78)51(35(101-65)20-86-10)104-64-47(80)55(50(87-11)27(4)97-64)105-66-57(81)68(9)59(30(7)98-66)110-69(111-68)18-33(76)48(28(5)107-69)102-38-17-34(99-39-19-67(8,73(84)85)58(90-14)29(6)96-39)49(26(3)95-38)103-62(83)41-25(2)42(71)44(77)43(72)54(41)88-12/h15-16,26-30,33-39,45-53,55-60,63-66,74-81H,17-23H2,1-14H3/t26-,27-,28-,29+,30-,33-,34-,35-,36-,37+,38+,39-,45+,46-,47-,48-,49-,50+,51?,52-,53+,55+,56?,57-,58+,59-,60-,63+,64+,65+,66+,67+,68-,69?,70-/m1/s1

SMILES Code

COC[C@H]1O[C@H](C([C@H](C1O[C@@H]2O[C@@H]([C@@H]([C@H]([C@H]2O)O[C@@H]3O[C@@H]([C@H]4OC5(O[C@@]4([C@@H]3O)C)C[C@H]([C@@H]([C@H](O5)C)O[C@H]6C[C@H]([C@@H]([C@H](O6)C)OC(c7c(OC)c(Cl)c(O)c(Cl)c7C)=O)O[C@@H]8C[C@@]([C@H]([C@@H](O8)C)OC)([N+]([O-])=O)C)O)C)OC)C)O)OC)O[C@@H]9OC[C@@H]%10O[C@]%11(O[C@H]%10[C@H]9O)OC[C@H]([C@@H]%12OCO[C@@H]%11%12)OC(c%13c(O)cc(O)cc%13C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,631.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Limbrick EM, Yñigez-Gutierrez AE, Dulin CC, Derewacz DK, Spraggins JM, McCulloch KM, Iverson TM, Bachmann BO. Methyltransferase Contingencies in the Pathway of Everninomicin D Antibiotics and Analogues. Chembiochem. 2020 Dec 1;21(23):3349-3358. doi: 10.1002/cbic.202000305. Epub 2020 Sep 7. PMID: 32686210. 2: Limbrick EM, Graf M, Derewacz DK, Nguyen F, Spraggins JM, Wieland M, Ynigez- Gutierrez AE, Reisman BJ, Zinshteyn B, McCulloch KM, Iverson TM, Green R, Wilson DN, Bachmann BO. Bifunctional Nitrone-Conjugated Secondary Metabolite Targeting the Ribosome. J Am Chem Soc. 2020 Oct 28;142(43):18369-18377. doi: 10.1021/jacs.0c04675. Epub 2020 Oct 19. PMID: 32709196; PMCID: PMC8129991. 3: Starbird CA, Perry NA, Chen Q, Berndt S, Yamakawa I, Loukachevitch LV, Limbrick EM, Bachmann BO, Iverson TM, McCulloch KM. The Structure of the Bifunctional Everninomicin Biosynthetic Enzyme EvdMO1 Suggests Independent Activity of the Fused Methyltransferase-Oxidase Domains. Biochemistry. 2018 Dec 18;57(50):6827-6837. doi: 10.1021/acs.biochem.8b00836. Epub 2018 Dec 7. PMID: 30525509; PMCID: PMC7231510. 4: Hidai H. [Antibiotics--TAZ/PIPC, synercid, linezolid, everninomicin]. Nihon Rinsho. 2001 Apr;59(4):785-9. Japanese. PMID: 11305007. 5: Foster DR, Rybak MJ. Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin family. Pharmacotherapy. 1999 Oct;19(10):1111-7. doi: 10.1592/phco.19.15.1111.30576. PMID: 10512059. 6: Nakashio S, Iwasawa H, Dun FY, Kanemitsu K, Shimada J. Everninomicin, a new oligosaccharide antibiotic: its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity. Drugs Exp Clin Res. 1995;21(1):7-16. PMID: 7796712. 7: Nagashima S, Niwa M, Nishiki K, Hosoya T, Hishida A, Uematsu T. Effects of SCH27899 (Ziracin), an oligosaccharide everninomicin antibiotic, on urate kinetics in humans. Eur J Clin Pharmacol. 2004 Jun;60(4):255-64. doi: 10.1007/s00228-004-0755-y. Epub 2004 Apr 16. PMID: 15088132. 8: Aarestrup FM. Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH 27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin. Microb Drug Resist. 1998 Summer;4(2):137-41. doi: 10.1089/mdr.1998.4.137. PMID: 9651001. 9: Reimann H, Jaret RS, Sarre OZ. The chemistry of the everninomicin antibiotics. II. The structure of everninocin and its identification with curacin. J Antibiot (Tokyo). 1969 Mar;22(3):131-2. doi: 10.7164/antibiotics.22.131. PMID: 5789902. 10: Ganguly AK, Sarre OZ, Greeves D, Morton J. Letter: Structure of everninomicin D-1. J Am Chem Soc. 1975 Apr 2;97(7):1982-5. doi: 10.1021/ja00840a078. PMID: 1133407.